RAICHUR, Indien, 13. März 2025 /PRNewswire/ — Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED), ein führender Hersteller von Wirkstoffen und Formulierungen, gibt bekannt, dass der Sachverständigenausschuss (SEC) der CDSCO sein neues Prüfpräparat (Investigational New Drug, IND) –…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.